Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 13/20 | 1.00 |
| ▸ | PIK3CD | O00329 | 12/20 | 1.00 |
| ▸ | PIK3CB | P42338 | 12/20 | 1.00 |
| ▸ | PIK3CG | P48736 | 10/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1177072 | 0.99 | PIK3CA (1.00) | PIK3CAPIK3CDPIK3CBPIK3CGALDH1A1 | |
| SCHEMBL304345 | 0.80 | PIK3CA (1.00) | PIK3CAPIK3CDPIK3CBPIK3CGALDH1A1 | |
| SCHEMBL303137 | 0.75 | PIK3CD (1.00) | PIK3CAPIK3CDPIK3CBPIK3CGALDH1A1 | |
| SCHEMBL1853644 | 0.75 | PIK3CD (0.83) | PIK3CAPIK3CDPIK3CBPIK3CGALDH1A1 | |
| SCHEMBL10330144 | 0.71 | ALDH1A1 (1.00) | PIK3CAPIK3CDPIK3CBPIK3CGALDH1A1 | |
| SCHEMBL16880253 | 0.70 | ALDH1A1 (0.63) | PIK3CAPIK3CDPIK3CBPIK3CGALDH1A1 | |
| SCHEMBL1852944 | 0.70 | PIK3CD (1.00) | PIK3CAPIK3CDPIK3CBPIK3CGHTT | |
| SCHEMBL1176987 | 0.69 | PIK3CD (1.00) | PIK3CAPIK3CDPIK3CBPIK3CGALDH1A1 | |
| SCHEMBL1177420 | 0.68 | PIK3CD (0.59) | PIK3CAPIK3CDPIK3CBPIK3CGALDH1A1 | |
| SCHEMBL303269 | 0.68 | HTT (1.00) | PIK3CAPIK3CDPIK3CBPIK3CGALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7888344-B2 | Fused thiazole derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2011-02-15 | — | — | US | claimed |
| EP-1881827-B1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2011-09-28 | — | — | EP | disclosed |
| US-7888344-B2 | Fused thiazole derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2011-02-15 | — | — | US | disclosed |
| US-20080306060-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306060-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | MAP4K2, PDPK1, DAPK2 | PIK3CA 402/4885PIK3CD 571/4885PIK3CB 556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.